Sultanate of Oman. The Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC) of Oman has approved the addition of the following information in the package insert of meloxicam (Moven) capsules:
Drug Interaction: Meloxicam is not recommended with concomitant aspirin therapy due to the possibility of an increase in gastrointestinal ulceration or other complications.
Side Effects: Concomitant use of meloxicam, 15 mg once daily, and lithium doses ranging from 804 to 1072 mg twice daily are known to result in an increase in the mean pre-dose lithium concentration and the area under the curve by 21% when compared to subjects receiving lithium alone. This results from an inhibition of renal prostaglandin synthesis by meloxicam.
Pharmaceutical Newsletter of the Ministry of Health, Sultanate of Oman, vol. 10 (1), 2002.